ProMIS Neurosciences RSI
Was ist das RSI von ProMIS Neurosciences?
RSI von ProMIS Neurosciences, Inc. ist 47.13
Was ist die Definition von RSI?
Der relative Stärke-Index (RSI 14) ist ein Momentumindikator, der die Größe von Gewinnen und Verlusten über einen bestimmten Zeitraum vergleicht, um die Geschwindigkeit und die Änderung von Preisbewegungen eines Wertpapiers zu messen.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI von Unternehmen in Health Care Sektor auf OTC im Vergleich zu ProMIS Neurosciences
Was macht ProMIS Neurosciences?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Unternehmen mit rsi ähnlich ProMIS Neurosciences
- Meenakshi Enterprises hat RSI von 47.11
- Techno Electric & Engineering hat RSI von 47.11
- BSL hat RSI von 47.11
- Georgia Power Co hat RSI von 47.12
- TeamViewer AG hat RSI von 47.12
- Alphamab Oncology hat RSI von 47.12
- ProMIS Neurosciences hat RSI von 47.13
- Gulf Marine Services PLC hat RSI von 47.14
- Aytu BioPharma Inc hat RSI von 47.14
- Titanium Transportation I hat RSI von 47.14
- Queen's Gambit Growth Capital hat RSI von 47.14
- Victory Metals hat RSI von 47.14
- OP Bancorp hat RSI von 47.15